Postoperative radiotherapy in prostate cancer - Authors' reply
- PMID: 33933204
- DOI: 10.1016/S0140-6736(21)00268-3
Postoperative radiotherapy in prostate cancer - Authors' reply
Conflict of interest statement
CCP reports grants and personal fees from Bayer, Janssen, Clarity Pharmaceuticals, ITM Oncologics, and Myovant, unrelated to this Correspondence. PS receives honoraria from Astellas, Bayer, Bouchara, Ferring, Ipsen, Janssen, Sanofi, and Takeda, unrelated to this Correspondence. All other authors declare no competing interests.
Comment on
-
Postoperative radiotherapy in prostate cancer.Lancet. 2021 May 1;397(10285):1623. doi: 10.1016/S0140-6736(21)00273-7. Lancet. 2021. PMID: 33933203 No abstract available.
Publication types
MeSH terms
Grants and funding
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical
